|
KMID : 1137020100210010003
|
|
Journal of Gynecologic Oncology
2010 Volume.21 No. 1 p.3 ~ p.11
|
|
|
Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies
|
|
Robert A. Burger
|
|
|
Abstract
|
|
|
|
This article reviews the history and current status of vascular endothelial growth factor targeted therapy for the most common gynecologic malignancies - epithelial ovarian, endometrial and cervical cancers. The biologic rationale for targeting vascular endothelial growth factor (VEGF) for these disease sites is well-founded, and pre-clinical studies have supported the development of anti-VEGF agents. Their classification, known mechanisms of action, unique toxicities and clinical development are herein explored, the latter including issues related to study design, disease site and disease setting.
|
|
|
KEYWORD
|
|
|
Vascular endothelial growth factor, Ovarian neoplasms, Endometrial neoplasms, Cervical neoplasms, Angiogenesis, Bevacizumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|
|